Hexarelin：生长激素研究中最强效的GHRP

What Is Hexarelin?

Hexarelin, also known by its development name Examorelin, is a synthetic hexapeptide growth hormone secretagogue with the amino acid sequence His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2. It was developed as an optimized growth hormone-releasing peptide and has earned distinction as the most potent GHRP characterized in the scientific literature. In head-to-head comparisons, Hexarelin consistently produces the highest peak GH levels among commonly studied GHRPs, surpassing GHRP-2, GHRP-6, and Ipamorelin.

However, Hexarelin's exceptional potency comes with significant trade-offs. It produces the most pronounced off-target hormonal effects of any GHRP, including substantial elevations in cortisol and prolactin. Additionally, it is particularly susceptible to receptor desensitization with repeated dosing, a property that has limited its development as a sustained-use compound. Despite these limitations, Hexarelin has contributed valuable insights to GH axis research and has opened a separate line of investigation into potential cardiac protective effects.

Mechanism of Action

Hexarelin operates through the same primary mechanism as other GHRPs: agonism of the growth hormone secretagogue receptor type 1a (GHS-R1a). However, its particular structural modifications result in a binding profile that produces maximal receptor activation.

Pituitary Signaling

Upon binding to GHS-R1a on pituitary somatotrophs, Hexarelin activates the phospholipase C/IP3/calcium signaling cascade that is characteristic of ghrelin receptor activation. The magnitude of the GH response to Hexarelin suggests either a higher receptor affinity, greater efficacy in activating downstream signaling, or a combination of both compared to other GHRPs. Peak GH levels following Hexarelin administration in research settings have been reported to reach values substantially higher than those achieved with equimolar doses of GHRP-2 or GHRP-6.

Hypothalamic and Central Effects

Like other GHRPs, Hexarelin acts at the hypothalamic level to stimulate GHRH release and modulate somatostatin tone. However, its pronounced effects on cortisol and prolactin suggest broader activation of central neuroendocrine pathways. The cortisol elevation is believed to involve activation of corticotropin-releasing hormone (CRH) neurons or direct effects on ACTH release, while prolactin elevation may involve dopaminergic pathway modulation in the hypothalamus.

Cardiac Receptor Activity

A particularly interesting aspect of Hexarelin's pharmacology is its reported interaction with cardiac tissue. Research has identified specific binding sites for Hexarelin in heart tissue that appear to be distinct from the classical GHS-R1a receptor. Some investigators have proposed that Hexarelin may interact with a subtype of the ghrelin receptor or a related receptor (designated CD36 in some studies) that is expressed in cardiac cells. This cardiac binding activity has been the basis for a separate line of research into potential cardioprotective effects.

Key Properties

Property	Detail
Chemical Name	Hexarelin / Examorelin
Sequence	His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2
Molecular Weight	~887.0 Da
Peptide Length	6 amino acids (hexapeptide)
Primary Target	GHS-R1a (ghrelin receptor); also CD36 in cardiac tissue
GH Release Potency	Highest among GHRPs
Cortisol Effect	Moderate to significant increase
Prolactin Effect	Moderate to significant increase
Appetite Stimulation	Mild-Moderate
Desensitization Risk	High (most pronounced among GHRPs)
Half-Life	Approximately 60-70 minutes
Administration	Subcutaneous or intravenous (research settings)

Research Landscape

Maximum GH Secretory Capacity

Hexarelin has been used as a research tool for assessing the maximum GH-releasing capacity of the pituitary. Because it produces the largest acute GH pulse of any GHRP, it serves as a ceiling reference point for understanding the upper limits of somatotroph responsiveness. Studies comparing GH responses across different stimuli have used Hexarelin as the gold standard for maximum GHRP-mediated GH release.

Desensitization Studies

One of the most extensively studied aspects of Hexarelin is its propensity for receptor desensitization. Multiple studies have documented a progressive decline in the GH response to repeated Hexarelin administration. In typical research protocols, the GH response may begin to diminish within days of daily dosing, and by several weeks, the response can be substantially attenuated compared to the initial administration. This desensitization appears to involve downregulation of GHS-R1a receptor expression and possibly altered intracellular signaling efficiency.

The desensitization phenomenon with Hexarelin has been more pronounced and more rapid in onset than that observed with other GHRPs like GHRP-2 or GHRP-6, and it stands in contrast to Ipamorelin, which shows relatively minimal desensitization in comparative studies. This difference has been an important research finding, as it suggests that the desensitization response is not simply a property of GHS-R1a activation in general but may depend on the specific agonist and the magnitude of receptor stimulation.

Cardiac Research

Perhaps the most novel area of Hexarelin research involves its potential effects on the cardiovascular system. Preclinical studies have explored several cardiac-related properties:

• Cardiac protection in ischemia models: Animal studies have examined whether Hexarelin can provide protection against ischemia-reperfusion injury in cardiac tissue. Some findings have suggested reduced infarct size and improved functional recovery in treated animals.
• Cardiac function parameters: Research has investigated effects on left ventricular function and cardiac output, with some studies reporting positive effects in models of cardiac dysfunction.
• GH-independent cardiac effects: Intriguingly, some of these cardiac effects appear to be independent of GH release, suggesting a direct action of Hexarelin on cardiac tissue through its interaction with cardiac binding sites (potentially CD36 or a related receptor). This has been demonstrated in studies where GH receptor blockade did not fully abolish the cardiac effects.
• Anti-atherosclerotic properties: Some preclinical work has examined potential effects on cholesterol metabolism and atherosclerotic plaque development, potentially mediated through CD36 interactions on macrophages.

It is important to note that these cardiac findings are primarily from preclinical (animal) models, and translation to human applications remains uncertain and requires substantially more research.

Comparative Potency Studies

Hexarelin has served as an essential comparator in studies ranking GHRP potency. A landmark aspect of this research is the demonstration that while Hexarelin produces the highest acute GH peak, this does not necessarily translate to the most effective sustained GH elevation due to desensitization. This finding has been instructive in illustrating that maximal acute potency and optimal long-term efficacy are distinct considerations in secretagogue research.

Safety Profile

Safety observations for Hexarelin come primarily from short-term clinical studies and preclinical research. This information is for educational purposes only and does not constitute medical advice.

• Cortisol elevation: Hexarelin produces the most significant cortisol elevation among GHRPs, which is a primary concern for any sustained use. Chronic cortisol elevation is associated with a range of adverse metabolic and immunological effects.
• Prolactin elevation: Similarly, the prolactin-elevating effects of Hexarelin are the most pronounced in the GHRP class. Sustained prolactin elevation can have significant endocrine implications.
• Desensitization: The progressive loss of GH-releasing efficacy with repeated dosing is the most frequently cited limitation. This desensitization can be substantial and may take an extended washout period to reverse.
• ACTH effects: Increases in ACTH have been documented alongside cortisol elevation, confirming HPA axis stimulation.
• Injection site reactions: Typical mild and transient local reactions at injection sites have been reported.

Hexarelin is not approved as a therapeutic agent and is available for research purposes only.

Comparison: Hexarelin vs. Other GHRPs

Property	Hexarelin	GHRP-2	GHRP-6	Ipamorelin
Peak GH Release	Highest	High	Moderate-High	Moderate
Selectivity	Lowest	Moderate	Low-Moderate	Highest
Desensitization	Most Pronounced	Moderate	Moderate	Minimal
Cortisol Impact	Significant	Mild-Moderate	Mild	Negligible
Prolactin Impact	Significant	Mild-Moderate	Mild	Negligible
Cardiac Research	Extensive	Limited	Some	Limited
Sustained Efficacy	Poor (desensitization)	Good	Good	Best

Current Status

Hexarelin remains a valuable research tool, particularly in studies requiring maximum acute GH stimulation and in cardiac research. Its clinical development as a sustained GH secretagogue was essentially halted due to desensitization concerns and its broad hormonal effects. However, the cardiac protection line of research continues to attract interest, and Hexarelin's potency ensures its ongoing utility as a reference compound in comparative GHRP studies.

For a broader overview of the GH secretagogue family and how different compounds compare, see Growth Hormone Secretagogues: Complete Guide.

This article is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare professional before making any decisions related to peptides or other compounds.